After trying multiple antidepressants without finding meaningful relief, you might wonder if anything will ever help. The answer is yes—but it requires moving beyond the standard approach that hasn’t been working. Difficult-to-treat depression affects 30-40% of patients treated with antidepressants, and newer treatment options specifically address this challenge (Fiorillo et al., 2025). Understanding what’s available, how different treatments work, and which might be appropriate for your situation empowers you to have informed conversations with your psychiatrist about next steps that could finally provide the relief you’ve been seeking.
Understanding Your Treatment Options
When standard antidepressants haven’t worked, several pathways exist for moving forward. These aren’t ranked as “better” or “worse”—they’re different approaches that work through distinct mechanisms, and what helps one person may not help another. The goal is finding what works for your individual situation.
Medication augmentation adds another medication to boost your current antidepressant’s effectiveness rather than replacing it entirely. Common augmentation agents include atypical antipsychotics like aripiprazole, lithium, or thyroid hormone. Research shows these strategies can help 30-40% of people who haven’t responded to antidepressants alone. The advantage is potentially building on any partial response you may have experienced, but it also means taking multiple medications with combined side effect risks.
Switching to a different medication class explores antidepressants that work through different mechanisms than what you’ve already tried. If you’ve only tried SSRIs, switching to an SNRI, bupropion, or mirtazapine might provide better results since they affect different neurotransmitter systems. However, if you’ve already tried multiple medications from various classes without success, simply switching to another oral antidepressant often yields similar disappointing outcomes.
Brain stimulation therapies offer non-medication approaches that work directly on brain circuits involved in depression. These include electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS). ECT remains highly effective for severe, treatment-resistant depression but requires anesthesia and can affect memory. TMS provides a non-invasive, medication-free option with minimal side effects. DBS involves surgical implantation and is typically reserved for the most severe cases that haven’t responded to other interventions.
Novel pharmacotherapies target different brain systems than traditional antidepressants. SPRAVATO® (esketamine) works on NMDA receptors rather than serotonin systems, offering rapid antidepressant effects for some people with difficult-to-treat depression. Unlike oral antidepressants that take weeks to work, SPRAVATO® can produce improvements more quickly, though it requires administration in a clinical setting with monitoring.
How Treatments Differ in Mechanism
Understanding why different treatments might work when others haven’t requires looking at how they affect your brain. Traditional antidepressants primarily target monoamine neurotransmitters—serotonin, norepinephrine, and dopamine. If your depression doesn’t respond adequately to these medications, it suggests your depression may involve other biological pathways.
Glutamate system modulation represents a promising alternative approach, with treatments like SPRAVATO® targeting NMDA receptors (Lucido & Dunlop, 2025). This fundamentally different mechanism explains why some people who haven’t responded to traditional antidepressants experience improvement with glutamatergic agents. Your brain’s neurotransmitter systems interact in complex ways, and accessing depression through a different entry point can sometimes achieve what previous approaches couldn’t.
Brain stimulation therapies bypass medication altogether by directly affecting neural circuits. Transcranial magnetic stimulation uses magnetic pulses to stimulate or modulate brain areas involved in mood regulation, essentially helping your brain create healthier neural pathways. At Catalyst Psychiatry, the BrainsWay Deep TMS system penetrates deeper than standard TMS coils, potentially reaching more brain structures involved in depression. This technology has been FDA-cleared for difficult-to-treat depression since 2008, with research supporting its efficacy.
The advantage of having multiple treatment approaches is that lack of response to one doesn’t predict response to another. Just because SSRIs didn’t work doesn’t mean you won’t respond to TMS. Just because you’ve tried several oral medications doesn’t mean SPRAVATO® won’t help. Each approach targets different aspects of depression’s underlying neurobiology.
Evaluating Options for Your Situation
Not every treatment is appropriate for every person, and several factors influence which options make sense to explore next. Your treatment history, symptom severity, medical conditions, lifestyle considerations, and personal preferences all matter when deciding what to try.
Consider your treatment history carefully. How many medications have you tried, and from which classes? Have you given each an adequate trial at therapeutic doses? Have you tried augmentation strategies? Understanding exactly what you’ve already attempted helps identify gaps and informs which direction to move next. The team at Catalyst Psychiatry specializes in reviewing treatment histories to determine appropriate next steps based on evidence-based assessment.
Symptom severity affects treatment choice. For severe depression with significant impairment or safety concerns, more aggressive interventions like ECT might be most appropriate despite potential side effects. For moderate difficult-to-treat depression, starting with less invasive options like TMS or medication augmentation makes sense. The goal is matching intervention intensity to your situation while respecting your preferences.
Practical considerations matter too. SPRAVATO® requires multiple visits per week initially, with treatment taking several hours including monitoring time. TMS involves daily sessions for several weeks. Medication changes can be managed with less frequent appointments. Insurance coverage varies, and some treatments require prior authorization demonstrating you’ve tried specific numbers and types of medications first.
At Catalyst Psychiatry, the emphasis on patient-centered collaboration means you’ll participate in decisions about your treatment plan. The practice philosophy recognizes that you’ll ultimately decide what’s best for your life after understanding your options, potential benefits, and realistic expectations. This approach respects your autonomy while providing expert guidance.
What to Expect with Advanced Treatments
If you’re considering treatments beyond standard antidepressants, understanding what’s involved helps you make informed decisions. Deep TMS typically requires 36 treatment sessions over 6-9 weeks, with each session lasting about 20 minutes. You remain awake and alert throughout. The most common side effects are mild headache and discomfort at the treatment site during treatment. Unlike ECT, TMS doesn’t require anesthesia and doesn’t affect memory.
SPRAVATO® involves twice-weekly nasal spray administrations initially, then weekly, then every-other-week for maintenance. You must remain at the treatment center for at least two hours after each dose for monitoring. The medication can cause sedation, dissociation, and increased blood pressure, which is why supervised administration is required. Not all patients respond to SPRAVATO®, and results vary by individual, but research shows some people with difficult-to-treat depression experience significant improvement.
Insurance coverage for these treatments has improved significantly, though prior authorization requirements still exist. Most insurance companies covering TMS want documentation of failure to respond to four or more antidepressants with at least one from a different class, plus failure to respond to weekly therapy. SPRAVATO® is covered by most insurance plans for patients meeting difficult-to-treat depression criteria. Catalyst Psychiatry works with insurance companies to obtain necessary authorizations and also offers out-of-pocket options for TMS at discounted rates.
As the only provider of Deep TMS in the middle and lower Willamette Valley, Catalyst Psychiatry has been offering this advanced treatment since March 2019. Patients who have completed Deep TMS treatment have reported dramatic improvements in depressive symptoms and overall well-being, experiencing the kind of relief that multiple medication trials couldn’t provide.
Making the Decision
Deciding what to try next when standard treatments haven’t worked requires gathering information, weighing options, and having honest conversations with your psychiatrist. Here are three steps to move forward this week:
Schedule a comprehensive treatment review. Bring documentation of everything you’ve tried—medication names, doses, durations, side effects, and degree of response. This information helps your psychiatrist identify patterns and gaps in your treatment history. If you’ve seen multiple providers, gathering records from previous treatment can reveal important details.
Clarify your priorities and concerns. What matters most to you—minimizing side effects, avoiding medication if possible, getting faster results, or finding something you haven’t tried yet? What are you willing to commit to in terms of time and frequency of treatment? Being clear about your priorities helps guide treatment selection toward options you’ll actually follow through with.
Ask specific questions about proposed treatments. How does this treatment work differently than what I’ve tried? What’s the expected timeline for seeing results? What are common side effects, and how are they managed? What does the research show about effectiveness for treatment-resistant depression? What happens if this doesn’t work—what would we try next? These questions help you understand whether a proposed treatment makes sense for your situation.
Access to Specialized Care in Corvallis
For Willamette Valley residents struggling with difficult-to-treat depression, accessing advanced treatments doesn’t require traveling to Portland or Eugene. Catalyst Psychiatry offers both Deep TMS and SPRAVATO® right in Corvallis, with a treatment environment designed to promote feelings of wellness—complete with Willamette River views, spa-like atmosphere, and amenities that make treatment sessions more comfortable.
The practice is currently accepting new patients specifically for TMS and SPRAVATO® treatment, recognizing the urgent need for specialized care among people with difficult-to-treat depression. The team’s approach emphasizes accurate diagnosis using DSM-5 criteria, evidence-based treatment recommendations reflecting the latest research, and collaborative decision-making that respects patient autonomy.
Results vary by individual, and no treatment works for everyone. However, if you’ve exhausted standard approaches without finding adequate relief, exploring specialized treatment options offers hope beyond continuing the same medication strategies that haven’t been working. The decision is yours, and comprehensive evaluation helps determine whether advanced treatments might be appropriate for your situation.
Moving Forward
Difficult-to-treat depression doesn’t mean untreatable depression—it means you need different approaches than what you’ve already tried. Understanding your options, how they work, and what’s involved in pursuing them empowers you to have informed discussions with your psychiatrist about next steps. Whether that means trying medication augmentation, switching to a novel agent, or exploring brain stimulation therapies, pathways exist beyond the treatments that haven’t provided relief.
If you’re tired of cycling through similar medications with disappointing results, consider scheduling a consultation to discuss advanced treatment options. At Catalyst Psychiatry, the focus is on providing access to the latest evidence-based treatments for difficult-to-treat depression, delivered with compassion and expertise by professionals who understand how frustrating the search for effective treatment can be. You can also complete a TMS self-assessment to learn more about whether this treatment might be appropriate for you.
Disclaimer: This blog is for informational purposes only and does not constitute medical advice. Treatment outcomes vary by individual. Advanced treatments for depression are not appropriate for everyone, and comprehensive evaluation determines candidacy. If you are experiencing thoughts of self-harm or suicide, please call 988 for the Suicide & Crisis Lifeline or go to your nearest emergency room.
References
Fiorillo, A., Demyttenaere, K., Martiadis, V., & Martinotti, G. (2025). Editorial: Treatment resistant depression (TRD): epidemiology, clinic, burden and treatment. Frontiers in Psychiatry, 16, 1588902.
Janik-Łoszewska, O., et al. (2025). Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways. GeroScience, 47(4), 5543-5558.
Lucido, M.J., & Dunlop, B.W. (2025). Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges. Brain Sciences, 15(2), 161.